Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

BCRX Insider Trading

BIOCRYST PHARMACEUTICALS INC | Biological Products, (No Diagnostic Substances)

Comprehensive Trading Performance Summary

The investment history of corporate insiders at BIOCRYST PHARMACEUTICALS INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2009-02-03 18:53 2009-01-30 Stonehouse Jon P Director, Officer - President & CEO BUY $1.62 3,000 $4,845 103,603 +3.0%
2008-12-03 01:56 2008-12-01 Stonehouse Jon P Director, Officer - President & CEO BUY $1.48 55,000 $81,450 155,603 +54.7%
2008-11-25 01:10 2008-11-20 Baker Bros. Capital (GP), LLC 10% owner BUY $0.99 475 $471 109,716 +0.4%
2008-11-25 00:55 2008-11-20 Baker Brothers Life Sciences Capital (GP), LLC 10% owner BUY $0.99 341,989 $339,150 4,348,466 +8.5%
2008-11-25 00:51 2008-11-20 Baker Biotech Capital (GP), LLC 10% owner BUY $0.99 108,203 $107,305 1,758,493 +6.6%
2008-11-25 00:47 2008-11-20 14159 capital (GP), LLC 10% owner BUY $0.99 9,327 $9,250 136,688 +7.3%
2008-11-25 00:41 2008-11-20 Baker / Tisch Capital (GP), LLC 10% owner BUY $0.99 2,284 $2,265 27,326 +9.1%
2008-11-04 01:34 2008-11-03 Stonehouse Jon P Director, Officer - President & CEO BUY $1.75 25,000 $43,730 100,603 +33.1%
2008-08-13 21:58 2008-08-12 Stonehouse Jon P Director, Officer - President & CEO BUY $3.10 2,300 $7,124 75,603 +3.1%
2008-08-13 21:26 2008-08-11 Stonehouse Jon P Director, Officer - President & CEO BUY $2.95 7,700 $22,736 73,303 +11.7%
2008-08-05 01:47 2008-08-04 Grant Stuart Officer - SR VP & CFO BUY $2.82 3,000 $8,466 3,000 +100.0%
2008-08-05 01:38 2008-08-04 Stonehouse Jon P Director, Officer - President & CEO BUY $2.82 240 $677 65,603 +0.4%
2008-08-05 01:22 2008-07-31 DARWIN MICHAEL A Officer - Principal Accounting Officer BUY $2.82 1,709 $4,823 3,048 +127.6%
2008-02-04 21:20 2008-01-31 Stonehouse Jon P Director, Officer - President & CEO BUY $3.50 3,000 $10,506 65,363 +4.8%
2008-02-04 21:04 2008-01-31 DARWIN MICHAEL A Officer - Principal Accounting Officer BUY $3.50 1,339 $4,689 1,339 +100.0%
2007-09-06 18:08 2007-09-04 BENNETT J CLAUDE Director, Officer - Chief Operating Officer OPT+S $12.00 20,000 $240,000 65,730 0.0%
2007-08-15 00:21 2007-08-13 Stonehouse Jon P Director, Officer - President & CEO BUY $9.90 9,900 $97,992 62,363 +18.9%
2007-08-08 18:09 2007-08-06 FEATHERINGILL WILLIAM W Director, 10% owner BUY $7.80 831,538 $6,485,996 831,538 +100.0%
2007-08-03 00:41 2007-07-31 Stonehouse Jon P Director, Officer - CEO BUY $7.06 2,463 $17,376 52,463 +4.9%
2007-08-03 00:37 2007-07-31 Nugent Jonathan M Officer - VP Corp Communications BUY $7.06 285 $2,011 508 +127.8%
2007-08-03 00:28 2007-07-31 ALEXANDER W JAMES Officer - SR. VP, Chief Medical Officer BUY $7.06 2,374 $16,749 3,659 +184.7%
2007-02-02 20:53 2007-01-31 Nugent Jonathan M Officer - VP Corp Communications BUY $8.64 223 $1,928 223 +100.0%
2007-02-02 20:42 2007-01-31 RIGGS RANDALL B Officer - Senior VP Business Development BUY $8.64 1,184 $10,235 1,928 +159.1%
2006-09-06 01:44 2006-09-01 Nugent Jonathan M Officer - VP Corp Communications OPT+S $10.19 5,600 $57,089 0 0.0%
2006-08-15 21:09 2006-08-14 ALEXANDER W JAMES Officer - SR. VP, Chief Medical Officer BUY $9.00 1,285 $11,565 1,285 +100.0%
2006-08-03 00:37 2006-07-31 RIGGS RANDALL B Officer - Senior VP Business Development BUY $9.69 744 $7,209 744 +100.0%
2006-05-11 20:30 2006-05-10 BENNETT J CLAUDE Director, Officer - President BUY $6.50 6,563 $42,660 49,559 +15.3%
2006-05-05 23:26 2006-05-03 BENNETT J CLAUDE Director, Officer - President SELL $15.13 26,243 $397,133 42,996 -37.9%
2006-05-05 23:26 2006-05-03 BENNETT J CLAUDE Director, Officer - President BUY $6.50 35,000 $227,500 69,239 +102.2%
2006-05-05 23:18 2006-05-03 SEIDENBERG BETH C Director BUY $15.34 3,000 $46,030 3,000 +100.0%
2006-04-05 21:53 2006-04-03 BENNETT J CLAUDE Director, Officer - President OPT+S $18.02 10,000 $180,249 34,239 0.0%
2006-03-17 21:03 2006-03-15 DARWIN MICHAEL A Officer - Chief Financial Officer OPT+S $19.21 22,650 $435,177 668 0.0%
2006-03-07 18:58 2006-03-03 BENNETT J CLAUDE Director, Officer - President OPT+S $21.00 10,000 $209,973 33,555 0.0%
2006-03-08 01:38 2006-03-03 BUGG CHARLES E Director, Officer - Chairman OPT+S $20.64 50,000 $1,032,240 62,439 0.0%
2006-03-06 21:26 2006-03-03 RIGGS RANDALL B Officer - Senior VP Business Development SELL $20.38 1,512 $30,819 0 -100.0%
2006-02-15 00:18 2006-02-10 FEATHERINGILL WILLIAM W Director SELL $16.49 16,200 $267,099 925,000 -1.7%
2006-02-15 00:10 2006-02-13 BENNETT J CLAUDE Director, Officer - President OPT+S $16.94 3,000 $50,826 32,005 0.0%
2005-09-28 01:33 2005-09-26 BUGG CHARLES E Director, Officer - CEO, Chairman OPT+S $10.00 95,000 $950,323 57,557 0.0%
2005-03-03 21:02 2003-03-11 SHERRILL JOSEPH H JR Director BUY $1.06 2,700 $2,862 451,900 +0.6%
2004-04-29 21:57 2004-04-27 BUGG CHARLES E Director, Officer - CEO OPT+S $9.51 85,000 $808,410 52,557 0.0%
2004-03-16 20:49 2004-03-12 DARWIN MICHAEL A Officer - CFO OPT+S $8.06 5,650 $45,533 668 0.0%
2003-08-06 00:26 2003-08-04 SHERRILL JOSEPH H JR Director BUY $4.05 2,100 $8,497 484,300 +0.4%
2003-08-04 19:34 2003-08-01 SHERRILL JOSEPH H JR Director BUY $3.99 3,600 $14,363 482,200 +0.8%
SHOW ENTRIES

How to Interpret $BCRX Trades

Not every insider transaction in BIOCRYST PHARMACEUTICALS INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $BCRX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for BCRX

Insider activity data for BIOCRYST PHARMACEUTICALS INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $BCRX, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.